Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 27, 2025

Primary Completion Date

April 1, 2026

Study Completion Date

June 1, 2026

Conditions

Clear Cell Renal Cell Carcinoma and Glioblastoma

Interventions

DRUG

68Ga-XT771

68Ga-XT771 is injected intravenously with a dose of 4-8 mCi

Trial Locations (1)

RECRUITING

Chinese PLA General Hospital, Beijing

All Listed Sponsors

collaborator

Sinotau Pharmaceutical Group

INDUSTRY

lead

Chinese PLA General Hospital

OTHER